Heart failure with reduced ejection fraction: LCZ696, an angiotensin receptor - neprilysin inhibitor, granted FDA priority review
The FDA ( Food and Drug Administration ) has granted priority review designation to LCZ696, an investigational medicine for the treatment of heart failure with reduced ejection fraction ( HFrEF ).
T ...
read article